Go Deep
iBio, Inc.
iBio, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 22,710 | -2.4 | 0.59 | 0.03 | 74.14 |
| Oct 2026 | 22,707 | -2.4 | 0.59 | 0.03 | 74.34 |
| Oct 2026 | 22,734 | -2.4 | 0.57 | 0.03 | 72.58 |
| Oct 2026 | 22,745 | -2.4 | 0.57 | 0.03 | 72.07 |
| Oct 2026 | 22,642 | -2.6 | 0.62 | 0.03 | 77.84 |
| Oct 2026 | 22,610 | -2.6 | 0.63 | 0.03 | 79.45 |
| Oct 2026 | 22,705 | -2.5 | 0.59 | 0.03 | 74.00 |
iBio, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 100,000.0 |
| Net Profit | -10,601,000.0 | -7,730,000.0 | -8,993,000.0 | -5,720,000.0 |
| EPS | — | -0.1 | -0.1 | -0.1 |
iBio, Inc. Revenue & Profit: Last 5 Years
| Line Item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
| Revenue | 100,000.0 | 400,000.0 | 225,000.0 | 0.0 | — |
| Net Profit | -33,044,000.0 | -18,377,000.0 | -24,907,000.0 | -65,010,000.0 | — |
| EPS | — | -1.8 | -6.5 | -106.2 | -115.6 |
iBio, Inc. Balance Sheet
| Line Item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
| Total Assets | 99,110,000.0 | 23,185,000.0 | 28,734,000.0 | 41,207,000.0 | — |
| Total Liabilities | 13,397,000.0 | 8,305,000.0 | 7,410,000.0 | 25,826,000.0 | — |
| Total Equity | 85,713,000.0 | 14,880,000.0 | 21,324,000.0 | 15,381,000.0 | — |
Owes vs Owns
iBio, Inc. owed $0.14 for every $1 it owned in Jun 2026, down from $0.63 in Jun 2023.
| Period | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.14× | 0.36× | 0.26× | 0.63× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
iBio, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Jun 2026
Cash & short-term investments 88.8%Receivables 1.1%Fixed assets (tangible) 4.8%Intangible assets 1.8%Other assets 3.4%
How it's funded — Jun 2026
Short-term debt 0.6%Long-term debt 1.7%Payables 4.5%Other liabilities 6.8%Shareholders' equity 86.5%
| Line Item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 88.0 | 8.6 | 14.2 | 4.3 |
| Receivables | 1.1 | 0.1 | 0.7 | 0.2 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 4.8 | 5.3 | 6.4 | 7.6 |
| Intangible assets | 1.8 | 6.8 | 5.4 | 5.4 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 3.4 | 2.4 | 2.1 | 23.8 |
| Liabilities & equity | ||||
| Short-term debt | 0.5 | 0.8 | 0.2 | 12.9 |
| Long-term debt | 1.7 | 2.2 | 0.8 | 3.5 |
| Payables | 4.4 | 2.2 | 0.4 | 1.8 |
| Other liabilities | 6.8 | 3.2 | 6.1 | 7.6 |
| Shareholders' equity | 85.7 | 14.9 | 21.3 | 15.4 |
| Net tangible assets | 83.9 | 8.0 | 16.0 | 10.0 |
iBio, Inc. Cash Flow
| Line Item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
| Operating Activities | -23,218,000.0 | -15,304,000.0 | -18,554,000.0 | -30,436,000.0 | — |
| Investing Activities | -31,999,000.0 | 742,000.0 | 906,000.0 | 7,009,000.0 | — |
| Financing Activities | 103,048,000.0 | 8,929,000.0 | 24,494,000.0 | 2,301,000.0 | — |